thought call
continu face headwind sever front across core businesseswith
three cornerston franchis enbrel neulasta/neupogen anemia expect
declin go forward accompani thought guard tone
compani exampl call enbrel continu face net sell price
declin y/i esa portfolio hit lower net sell price potenti increas aranesp
competit neulasta declin tie declin use myleosupress
chemo trend arent new like factor stock believ
absent revers trend upsid share could prove difficult
optimist aimovig migrain well cgrp class overal
dont think contribut enough significantli rais product revenu growth
even said like posit aimovig first mover
allow partner novarti set commerci stage price contract
earli exposur headach specialist deal front capac
transform type transact could impact current revenu trend
pipelin valu howev absent clear bd strategi materi better demand
trend repatha aimovig continu remain ew pt
aimovig like first-in-class set stage new migrain market
despit neg commerci trend current base busi like
potenti set aimovig concern potenti revenu contribut
enough near-term expect partner novarti strateg
contract payer ensur access ahead potenti launch class
amgn/lli takeaway migrain physician lunch biohaven
pharmaceut inc updat view rimegep
 thought ubrogep oral cgrp phase data migrain
model chang given recent trend commentari updat model
forecast non-gaap ep non-gaap ep
page detail
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight despit improv pipelin
committ y/i dividend increas
improv margin compani revenu growth
outlook remain modest contribut
evolocumab kyproli alreadi reflect
estim view risk/reward profil
balanc expect market look greater
revenu accler cost save
pipelin adopt faster
anticip increas visibl biosimilar
threat neulasta/enbrel unlik materi
near-to-short term
launch slower expect
increas certainti time
biosimilar enbrel neulasta launch like
come signific price discount brand
made modest chang model reduc outlook product
includ notabl sensipar aranesp lower
revenu forecast respect vs prior likewis
lower total opex estim result non-gaap
estim respect vs prior
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
